Log in
NASDAQ:GBIO

Generation Bio Stock Forecast, Price & News

$30.11
+2.73 (+9.97 %)
(As of 09/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$27.31
Now: $30.11
$30.40
50-Day Range
$19.30
MA: $25.90
$31.84
52-Week Range
$17.00
Now: $30.11
$32.18
Volume222,012 shs
Average Volume206,637 shs
Market Capitalization$1.40 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Generation Bio Co. develops gene therapies for the treatment of genetic diseases. It focuses in the areas of liver, eye, muscle, and brain disorders. Generation Bio Co. was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. The company was founded in 2016 and is based in Cambridge, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.43 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GBIO
CUSIPN/A
CIKN/A
Phone857-529-5908

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees85
Market Cap$1.40 billion
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$30.11
+2.73 (+9.97 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for GBIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Generation Bio (NASDAQ:GBIO) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Generation Bio?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Generation Bio in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Generation Bio
.

When is Generation Bio's next earnings date?

Generation Bio is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Generation Bio
.

How were Generation Bio's earnings last quarter?

Generation Bio Co. (NASDAQ:GBIO) announced its quarterly earnings data on Tuesday, August, 11th. The company reported ($1.50) EPS for the quarter, missing the Zacks' consensus estimate of ($0.60) by $0.90.
View Generation Bio's earnings history
.

What price target have analysts set for GBIO?

4 analysts have issued 1 year target prices for Generation Bio's shares. Their forecasts range from $28.00 to $38.00. On average, they expect Generation Bio's share price to reach $32.33 in the next twelve months. This suggests a possible upside of 7.4% from the stock's current price.
View analysts' price targets for Generation Bio
.

Who are some of Generation Bio's key competitors?

What other stocks do shareholders of Generation Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Generation Bio investors own include Docusign (DOCU), NVIDIA (NVDA), Overstock.com (OSTK), Boeing (BA), Pure Storage (PSTG), Mastercard (MA), QUALCOMM (QCOM), Riot Blockchain (RIOT), Twilio (TWLO) and Enphase Energy (ENPH).

Who are Generation Bio's key executives?

Generation Bio's management team includes the following people:
  • Dr. Cameron Geoffrey McDonough, Pres, CEO, Sec. & Director (Age 50, Pay $592.9k)
  • Dr. Douglas Kerr M.B.A., M.D., Ph.D., Chief Devel. Officer (Age 53, Pay $534.69k)
  • Dr. Mark D. Angelino Ph.D., Founder & COO (Age 47)
  • Dr. Robert Kotin, Founder & Advisor (Age 64)
  • Mr. Stephen J. DiPalma M.B.A., Interim Chief Financial Officer (Age 61)

When did Generation Bio IPO?

(GBIO) raised $126 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Generation Bio's stock symbol?

Generation Bio trades on the NASDAQ under the ticker symbol "GBIO."

When does the company's lock-up period expire?

Generation Bio's lock-up period expires on Wednesday, December 9th. Generation Bio had issued 10,500,000 shares in its public offering on June 12th. The total size of the offering was $199,500,000 based on an initial share price of $19.00. After the expiration of the company's lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Who are Generation Bio's major shareholders?

Generation Bio's stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (15.88%), FMR LLC (15.53%), Artal Group S.A. (6.31%), Bellevue Group AG (3.23%), Deerfield Management Company L.P. Series C (2.55%) and Victory Capital Management Inc. (1.90%).
View institutional ownership trends for Generation Bio
.

Which major investors are buying Generation Bio stock?

GBIO stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, FMR LLC, Artal Group S.A., Bellevue Group AG, Deerfield Management Company L.P. Series C, Victory Capital Management Inc., Harvard Management Co. Inc., and Logos Global Management LP.
View insider buying and selling activity for Generation Bio
.

How do I buy shares of Generation Bio?

Shares of GBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Generation Bio's stock price today?

One share of GBIO stock can currently be purchased for approximately $30.11.

How big of a company is Generation Bio?

Generation Bio has a market capitalization of $1.40 billion. Generation Bio employs 85 workers across the globe.

What is Generation Bio's official website?

The official website for Generation Bio is generationbio.com.

How can I contact Generation Bio?

Generation Bio's mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The company can be reached via phone at 857-529-5908 or via email at [email protected]

This page was last updated on 9/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.